Roche Stock

CHF249.10

0.20% yesterday

SIX Swiss Exchange, Aug 07, 05:31 pm CET

ISIN

CH0012032048

Symbol

ROG

Index

SMI, SMIM

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Roche Stock price

CHF249.10

-65.10 20.72% 5Y

SIX Swiss Exchange, Closing price Thu, Aug 07 2025

+0.50 0.20%

ISIN

CH0012032048

Symbol

ROG

Index

SMI, SMIM

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

CHF205.8b

Enterprise Value

CHF223.2b

Net debt

CHF17.3b

Cash

CHF17.3b

Shares outstanding

795.4m

Valuation (TTM | estimate)

P/E

24.1 | 11.9

P/S

3.4 | 3.3

EV/Sales

3.7 | 3.5

EV/FCF

14.8

P/B

6.5

Dividends

DPS

CHF9.70

Yield 1Y | 5Y

3.9% | 3.1%

Growth 1Y | 5Y

1.0% | 1.5%

Payout 1Y | 3Y

94.0% | 72.0%

Increased

25 Years

Financials (TTM | estimate)

Revenue

CHF60.5b | CHF63.3b

EBITDA

CHF20.4b | CHF25.3b

EBIT

CHF20.1b | CHF21.8b

Net Income

CHF8.3b | CHF16.6b

Free Cash Flow

CHF15.1b

Growth (TTM | estimate)

Revenue

3.0% | 4.6%

EBITDA

8.3% | 23.8%

EBIT

8.4% | 8.6%

Net Income

-28.0% | 100.1%

Free Cash Flow

31.8%

Financial Health

Equity Ratio

31.2%

Return on Equity

26.1%

ROCE

26.9%

ROIC

25.5%

Debt/Equity

1.1

EPS

CHF10.3

FCF per Share

CHF19.0

Short interest

Employees

103k

Rev per Employee

CHF590.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Roche Stock Analysis

Unlock Scores for Free

26 Analysts have issued a Roche forecast:

13x Buy

50%

9x Hold

35%

4x Sell

15%

More details on Analyst Estimates Including Price Targets

26 Analysts have issued a Roche forecast:

Buy

50%

Hold

35%

Sell

15%

Analyst Estimates with Stock Price Targets

Financial data from Roche

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	60,495 60,495	3% 3% 100%
- Direct Costs	15,783 15,783	1% 1% 26%
Gross Profit	44,712 44,712	4% 4% 74%
- Selling and Administrative Expenses	13,758 13,758	2% 2% 23%
- Research and Development Expense	13,042 13,042	1% 1% 22%
EBITDA	20,438 20,438	8% 8% 34%
- Depreciation and Amortization	351 351	4% 4% 1%
EBIT (Operating Income) EBIT	20,087 20,087	8% 8% 33%
Net Profit	8,277 8,277	28% 28% 14%

In millions CHF.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Roche Stock News

Neutral

GlobeNewsWire

●

6 days ago

Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.1 Results show that Susvimo's immediate and predictable durability was sustained over five years, with approx...

Neutral

Business Wire

●

6 days ago

Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with wet AMD. Results show that Susvimo's immediate and predict...

Negative

Fast Company

●

10 days ago

U.S. and European Union trade deal could cost the pharma industry up to $19 billion

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday.

More Roche News

Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Head office	Switzerland
CEO	Thomas Schinecker
Employees	103,249
Founded	1896
Website	www.roche.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now